| Name | XX-650-23 |
| Description | XX-650-23 is a small molecule CREB inhibitor that blocks the critical interaction between CREB and its required coactivator, CBP (CREB-binding protein), inducing apoptosis and cell cycle arrest in AML cells, and can be used in the study of acute myelogenous leukaemia (AML). |
| In vitro | During split Renilla luciferase complementation analysis, XX-650-23 exhibited an IC50 of 3.20 ± 0.43 μM in inhibiting the interaction between CREB and CBP [1]. Following treatment with XX-650-23 (100 pM - 10 μM) for 48 hours, four AML cell lines showed IC50 values ranging from 870 nM to 2.3 μM, defined as a 50% reduction in viable cell count compared to DMSO-treated cells, indicating the inhibition of AML growth by XX-650-23 [1]. |
| In vivo | XX-650-23 (2.3 mg/kg, intravenous injection) extends the survival of AML mouse model (NSG mice) and exhibits no toxicity[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 3.3 mg/mL (11.45 mM), Sonication is recommended.
DMSO : 80 mg/mL (277.49 mM), Sonication is recommended.
|
| Keywords | XX-650-23 | EpigeneticReaderDomain | Epigenetic Reader Domain | CREB | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Hematonosis Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
